血液筛检市场按检测类型、技术、最终用户、样本类型和检测模式划分－2025-2032年全球预测

预计到 2032 年，血液筛检市场规模将达到 106.4 亿美元，复合年增长率为 9.06%。

主要市场统计数据
基准年 2024	53.1亿美元
预计年份：2025年	57.9亿美元
预测年份：2032年	106.4亿美元
复合年增长率 (%)	9.06%

权威的介绍文章，阐述了诊断、工作流程需求和监管期望如何相互交织，从而重塑整个医疗保健系统的血液筛检策略。

血液筛检领域正处于一个关键的十字路口，临床需求、监管严格程度和技术能力正在融合，重新定义输血安全和感染疾病监测的管理方式。诊断灵敏度和特异性的提高使得早期检测成为可能，而实验室工作流程的整合和自动化则缩短了周转时间并减少了操作人员的差异。同时，人们对捐血者安全、新出现的病原体和供应链韧性的担忧日益加剧，促使相关人员重新评估检测流程和筹资策略。

医疗保健领导者如今必须平衡临床绩效与营运现实，例如人员配备限制、基础设施约束以及在分散式环境中对结果进行标准化解读的需求。同时，检测平台的设计和部署也日益受到跨领域优先事项的影响，例如资料互通性、品管和成本控制。本书清楚地介绍了诊断方法、检测模式和最终用户环境如何相互作用，从而影响血液筛检计画中的实际决策，为理解这些因素奠定了基础。

简明说明，介绍正在重塑血液筛检工作流程和医疗保健供应商参与的重要技术、监管和营运变革。

过去几年，在技术创新和不断变化的临床需求的驱动下，血液筛检领域发生了翻天覆地的变化。照护现场能力日趋成熟，减少了对中心实验室特定快速筛检需求的依赖；同时，实验室平台也实现了更高的自动化程度和数据连接性，以满足通量和可追溯性的需求。同时，分子诊断也从小众应用转向更广泛的操作整合，从而能够更准确地检测病原体和识别变异株。

这种转变也在改变采购行为和供应商合约模式。医疗系统越来越倾向于寻求不仅能提供诊断效能，还能提供生命週期支援、远端监控以及与实验室资讯系统无缝整合的解决方案。监管机构正在明确新检测方法和平台的审批路径，从而影响其推广应用的时间表。展望未来，互通性和模组化将成为平台选择的核心，因为医疗机构需要优先考虑灵活性，以适应新的威胁和不断变化的筛检方案。

分析和审查 2025 年美国实施的关税调整对营运和采购的累积影响，以及相关人员如何适应。

包括美国2025年关税调整在内的政策变化，为诊断相关人员的采购和供应链规划带来了新的考量。关税调整凸显了优先考虑区域製造、延长关键耗材前置作业时间以及实现供应商多元化以降低进口成本波动风险的筹资策略的重要性。这些政策也影响供应商的路线选择和库存策略，促使企业专注于总到岸成本，而不仅仅是单位成本。

在实践中，实验室管理人员和采购团队采取的应对措施包括加强需求预测、调整补货门槛，以及与供应商建立策略伙伴关係，从而实现在地化生产并达成优先分销协议。下游影响也延伸至资本设备采购週期，各机构需要权衡前期投资和持续依赖耗材之间的利弊。总体而言，2025 年的关税环境凸显了敏捷的供应链管治、情境规划以及能够应对地缘政治和政策衝击的合约条款的重要性。

本文从细分市场的观点主导，细緻入微分析了测试类型、技术模式、最终用户环境、样本处理和测试方式如何影响诊断选择和部署。

細項分析揭示了不同的临床需求和业务环境如何驱动不同检测类型、技术、最终用户、样本类型和检测模式的采用模式。乙型肝炎、C型肝炎、爱滋病毒和梅毒的筛检各自具有不同的敏感性、窗口期和确诊检测要求，这些因素都会影响演算法设计和复检管道。因此，诊断平台必须使分析效能与确诊追踪和捐血者咨询的实际需求相符。

化学冷光可提供高性能的讯号检测，而流式细胞技术支援某些免疫测定的多参数分析。免疫检测分为三种类型：化学冷光免疫检测、酵素结合免疫吸附检测法和免疫测量，每种类型在试剂稳定性、自动化适用性和成本方面各不相同。分子诊断包括等温扩增、次世代定序和聚合酵素链锁反应，每种技术在速度、灵敏度和资讯深度方面各有重点。最终使用者环境（血库、诊所、诊断实验室或医院）会影响工作流程的整合、人员能力和认证要求。检体类型（包括血浆、血清和全血）会影响分析前处理和检测方法的选择，而检测模式的选择（实验室检测或照护现场）则决定了检测的执行地点和结果的实施方式。这些细分视角为将临床目标与合适的诊断方案相匹配提供了一个实用的框架。

战略区域分析详细说明了医疗保健基础设施、管理体制和生产能力如何决定全球不同区域的血液筛检优先事项

区域动态以独特的方式影响技术采纳、监管管道和筹资策略，这些方式反映了医疗基础设施、政策重点和製造生态系统。在美洲，大型综合医疗系统和集中式血液服务往往倾向于采用高通量实验室平台和全面的品质框架。报销机制和国家指南进一步指导筛检演算法的实施和推广。

欧洲、中东和非洲呈现异质性环境，监管协调工作与基础建设能力有差异。有些市场重视严谨性和全程可追溯性，而有些市场则优先考虑经济实惠且适用于资源有限环境的稳健解决方案。在亚太地区，实验室网路的快速现代化、在地化生产能力的提升以及对分子诊断的投资正在加速先进平台的普及，尤其关注可扩展性和供应链本地化。了解这些区域差异有助于供应商和医疗机构调整其商业策略和实施计划，使其与当地需求和监管实际情况相符。

聚焦企业洞察，阐述供应商如何透过平台创新、服务模式和策略伙伴关係实现差异化，并获得长久的生存和市场认可。

血液筛检公司之间的竞争动态涵盖平台创新、试剂组合、服务模式和监管互动等多个面向。领先的供应商正透过投资自动化、数位化连接和检测范围来提升自身竞争力，以满足高效能血库和照护现场环境的需求。这些公司也在不断完善售后服务，例如远距离诊断支援、耗材管理和培训项目，以提高客户维繫并减少终端用户的操作障碍。

随着企业寻求加快检验流程并实现在地化生产，与临床实验室、学术中心和生产合作伙伴建立合作关係和共同开发安排变得越来越普遍。市场参与企业的策略重点领域包括更快的周转时间、更少的样本量需求以及增强的多重检测能力，以整合检测工作流程。能够清楚展示临床效用、运作可靠性和强大的售后支援的供应商更有可能获得医疗机构和血液服务机构的长期采购承诺。

向经营团队提出具体建议，以提高诊断灵活性、供应弹性、数位整合、员工准备度和协同检验，从而使筛检专案能够适应未来发展。

产业领导者应优先考虑一系列切实可行的措施，以平衡临床卓越性、营运韧性和商业性灵活性。首先，在采购决策中融入模组化理念，选择可逐步升级和具备多重检测能力的平台，从而减少对供应商的长期锁定，并随着检测需求的变化保持灵活性。其次，投资于供应链多元化和合约条款，以确保关键耗材的持续供应，同时抵御地缘政治和关税衝击。

第三，我们正在加速实验室资讯系统的数位化连接和整合，以提高结果可追溯性、品质监控以及各临床站点间的互通性。第四，我们正在製定清晰的推广蓝图，该路线图结合了实验室验证、员工培训和确认性检测途径，以在不影响安全性的前提下推广新技术。最后，我们正在与公共卫生机构和捐助机构合作进行试验计画，以在实际环境中检验新的检测通讯协定。这些倡议将有助于各机构管理风险、优化营运绩效并长期维持筛检品质。

我们采用透明的三管齐下的调查方法，结合相关人员访谈、监管指导审查和技术评估，为决策者提供可操作的见解。

本研究采用三角测量法，结合主要相关人员访谈、方案和监管指南审查以及系统性技术评估，得出可靠的结论。主要访谈对象包括实验室主任、输血医学专业人员、采购负责人和诊断设备供应商，旨在了解实际限制、推广应用驱动因素和实施经验。此外，还对官方监管指南、临床检验报告和设备标籤进行了结构化审查，以检验性能声明和管道要求，从而补充了这些定性资讯。

技术评估着眼于分析原则、运作特性以及跨平台类型的互通性。供应链分析则检视了製造布局、分销管道以及对关税敏感的采购依赖性，以了解风险因素。在整个过程中，所有证据都根据当地法规环境和典型的终端使用者营运模式进行了情境化处理。最终获得的洞见被综合提炼，旨在突出可操作的启示，而非抽象的预测，从而为临床、营运和商业相关人员的策略决策提供支持。

清晰、可操作的结论强调，以证据主导的采纳、供应链韧性和数位化整合是永续血液筛检计画的支柱。

血液筛检处于临床需求和技术能力的交汇点，这要求相关人员做出审慎的选择，以平衡分析能力和营运限制。新的工具和增强的连接性为缩短检测视窗、简化工作流程和提高可追溯性提供了契机，但成功应用取决于量身定制的实施策略，这些策略需反映当地的基础设施、人员能力和供应链实际情况。因此，决策者应优先考虑兼具临床价值和营运可行性的解决方案。

简而言之，采取务实且基于证据的方法至关重要：检验平台在其预期用途范围内的有效性，加强供应链管治以应对政策变化，并整合支持品质和互通性的数位化工作流程。如此一来，医疗机构和诊断服务提供者便可确保其血液筛检系统不仅技术先进，而且具有弹性、可扩展性，并与病患安全目标紧密契合。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 将人工智慧驱动的预测分析整合到血液疾病筛检工作流程中，以提高检测准确性
• 利用智慧型手机连接和远端实验室集成，扩大家用血液筛检套件，用于个人健康监测。
• 采用可同时检测多种血液标记的多重免疫检测，可提高诊断效率与通量。
• 在农村和医疗资源匮乏地区，对照护现场血液筛检设备的需求日益增长，以促进疾病的早期发现。
• 开发用于输血服务中血液传播病原体全面筛检的次世代定序平台
• 监管政策的改变推动了新兴市场血液筛检标准的统一，简化了全球检测通讯协定。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按检测类型分類的血液筛检市场

• 乙型肝炎筛检
• 丙型肝炎筛检
• 爱滋病毒筛检
• 梅毒筛检

9. 按技术分類的血液筛检市场

• 化学冷光
• 流式细胞技术
• 免疫检测
  • 化学冷光免疫检测
  • 酵素结合免疫吸附试验
  • 免疫检测
• 分子诊断
  • 等温扩增
  • 下一代定序
  • 聚合酵素链锁反应

第十章 依最终用户分類的血液筛检市场

• 血库
• 诊所
• 诊断实验室
• 医院

第十一章 依样本类型分類的血液筛检市场

• 电浆
• 血清
• 全血

第十二章 依检测模式分類的血液筛检市场

• 实验室
• 照护现场

第十三章 各地区血液筛检市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 按组别分類的血液筛检市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国血液筛检市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Grifols, SA
  • Bio-Rad Laboratories, Inc.
  • Ortho Clinical Diagnostics, Inc.
  • Hologic, Inc.
  • Terumo BCT, Inc.

The Blood Screening Market is projected to grow by USD 10.64 billion at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 5.31 billion
Estimated Year [2025]	USD 5.79 billion
Forecast Year [2032]	USD 10.64 billion
CAGR (%)	9.06%

An authoritative introduction framing how diagnostics, workflow imperatives, and regulatory expectation intersect to reshape blood screening strategy across healthcare systems

The landscape of blood screening is at a pivotal juncture where clinical expectation, regulatory rigor, and technological capability converge to redefine how transfusion safety and infectious disease surveillance are managed. Advances in diagnostic sensitivity and specificity are enabling earlier detection windows, while integrated laboratory workflows and automation are reducing turnaround times and operator variability. These developments are occurring alongside heightened attention to donor safety, pathogen emergence, and supply chain resilience, prompting stakeholders to reassess testing algorithms and procurement strategies.

Healthcare leaders must now balance clinical performance with operational realities, including staffing limitations, infrastructure constraints, and the need for standardized result interpretation across decentralized settings. At the same time, the design and deployment of testing platforms are increasingly influenced by cross-disciplinary priorities such as data interoperability, quality management, and cost containment. In this context, a clear-eyed introduction lays the foundation for understanding how diagnostic modalities, testing modes, and end-user environments interact to shape practical decision-making in blood screening programs.

A concise exploration of pivotal technological, regulatory, and operational shifts that are reshaping blood screening workflows and supplier engagement across care settings

Over recent years the blood screening landscape has experienced transformative shifts driven by technological innovation and evolving clinical imperatives. Point-of-care capabilities have matured, reducing the dependence on centralized laboratories for certain rapid screening needs, while laboratory-based platforms have embraced higher degrees of automation and data connectivity to meet throughput and traceability demands. Concurrently, molecular diagnostics have moved from niche applications toward broader operational integration, enabling more precise pathogen detection and variant discrimination.

These shifts have also produced changes in procurement behavior and vendor engagement models. Health systems are increasingly seeking solutions that deliver not only diagnostic performance but also lifecycle support, remote monitoring, and seamless integration with laboratory information systems. Regulatory agencies are clarifying pathways for novel assays and platforms, which in turn affects adoption timelines. Looking ahead, interoperability and modularity will be central to platform selection as institutions prioritize flexibility to respond to emergent threats and evolving screening protocols.

An analytical review of the cumulative operational and procurement impacts generated by United States tariff adjustments enacted in 2025 and how stakeholders adapted

Policy changes, including tariff adjustments implemented in the United States in 2025, have introduced new considerations into procurement and supply chain planning for diagnostic stakeholders. Tariff realignment has increased the prominence of sourcing strategies that prioritize regional manufacturing, longer lead times for critical consumables, and diversification of supplier bases to mitigate exposure to import-related cost volatility. These measures also influenced vendor routing decisions and inventory policies, prompting a closer examination of total landed cost beyond unit pricing.

In practice, laboratory managers and procurement teams responded by enhancing demand forecasting, revising reorder thresholds, and engaging in strategic partnerships with suppliers capable of local production or preferential distribution agreements. The downstream impacts extended to capital equipment procurement cycles as organizations evaluated tradeoffs between upfront investment and recurring consumable dependencies. Overall, the 2025 tariff environment underscored the necessity for agile supply chain governance, scenario planning, and contractual provisions that address geopolitical and policy-driven disruptions.

A nuanced segmentation-driven perspective showing how test type, technology modality, end-user setting, sample handling, and testing mode jointly inform diagnostic selection and deployment

Segmentation analysis illuminates how differentiated clinical needs and operational contexts drive adoption patterns across test types, technologies, end users, sample types, and testing modes. Within test types, screening for Hepatitis B, Hepatitis C, HIV, and Syphilis each carries distinct sensitivity, window-period, and confirmatory testing implications that affect algorithm design and reflex testing pathways. Diagnostic platforms must therefore align analytical performance with practical requirements for confirmatory follow-up and donor counselling.

Technology segmentation further clarifies capability tradeoffs: chemiluminescence delivers high-throughput signal detection while flow cytometry supports multi-parametric analysis for certain immunologic assessments. Immunoassays span chemiluminescence immunoassay, enzyme linked immunosorbent assay, and radioimmunoassay formats, each presenting different reagent stability, automation compatibility, and cost profiles. Molecular diagnostics encompass isothermal amplification, next generation sequencing, and polymerase chain reaction methods, offering varying balances of speed, sensitivity, and information depth. End-user contexts-blood banks, clinics, diagnostic laboratories, and hospitals-shape workflow integration, staff competencies, and accreditation requirements. Sample type considerations including plasma, serum, and whole blood influence pre-analytical handling and test selection, while testing mode choices between lab-based and point-of-care approaches determine where testing occurs and how results are actioned operationally. Together, these segmentation lenses provide a practical framework for pairing clinical aims with appropriate diagnostic solutions.

A strategic regional analysis detailing how healthcare infrastructure, regulatory regimes, and manufacturing capacity drive divergent blood screening priorities across global regions

Regional dynamics influence technology adoption, regulatory pathways, and procurement strategies in distinct ways that reflect healthcare infrastructure, policy priorities, and manufacturing ecosystems. In the Americas, large integrated health systems and centralized blood services tend to favor high-throughput laboratory platforms and comprehensive quality frameworks, while also supporting innovation pilots that bridge laboratory and point-of-care testing for decentralized contexts. Reimbursement structures and national guidelines further guide how screening algorithms are implemented and scaled.

Europe, Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with variable infrastructure capacities; some markets emphasize stringency and full traceability, whereas others prioritize affordable, robust solutions suited to constrained settings. In the Asia-Pacific region, rapid modernization of laboratory networks, local manufacturing capacity, and investments in molecular diagnostics are accelerating adoption of advanced platforms, with particular emphasis on scalability and supply chain localization. Awareness of these regional distinctions helps vendors and health systems tailor commercial strategies and implementation plans to local needs and regulatory realities.

A focused corporate insight outlining how suppliers are differentiating through platform innovation, service models, and strategic partnerships to win longevity and adoption

Competitive dynamics among companies operating in blood screening span platform innovation, reagent portfolios, service models, and regulatory engagement. Leading suppliers are differentiating through investments in automation, digital connectivity, and assay breadth to serve both high-throughput blood bank environments and decentralized point-of-care settings. These firms are also refining aftermarket offerings-including remote diagnostics support, consumable management, and training programs-to increase customer retention and reduce operational friction for end users.

Partnerships and co-development arrangements with clinical laboratories, academic centers, and manufacturing partners are increasingly common as companies seek to accelerate validation pathways and localize production. Strategic focus areas for market participants include improving turnaround times, reducing sample volume requirements, and enhancing multiplexing capabilities to consolidate testing workflows. Vendors that demonstrate clear evidence of clinical utility, operational reliability, and robust post-sales support are more likely to secure long-term procurement commitments from healthcare providers and blood services.

Concrete recommendations for executives to enhance diagnostic flexibility, supply resilience, digital integration, workforce readiness, and collaborative validation to future-proof screening programs

Industry leaders should prioritize a set of actionable measures that balance clinical excellence with operational resilience and commercial agility. First, embed modularity into procurement decisions by selecting platforms that allow incremental upgrades and multi-assay support to reduce long-term vendor lock-in and preserve flexibility as testing needs evolve. Second, invest in supply chain diversification and contractual clauses that protect against geopolitical and tariff-driven disruptions while ensuring continuity of critical consumables.

Third, accelerate integration of digital connectivity and laboratory information systems to improve result traceability, quality oversight, and interoperability across care settings. Fourth, develop clear adoption roadmaps that pair laboratory validation with staff training and confirmatory testing pathways so new technologies can be scaled without compromising safety. Finally, pursue collaborative pilot programs with public health agencies and donor organizations to validate novel testing protocols in real-world environments. These steps will help organizations manage risk, optimize operational performance, and sustain screening quality over time.

A transparent, tri-angulated research methodology combining stakeholder interviews, regulatory guidance review, and technology assessment to produce actionable insights for decision makers

This research synthesis draws on a triangulated methodology combining primary stakeholder interviews, protocol and regulatory guidance review, and systematic technology assessment to produce robust insights. Primary engagements included conversations with laboratory directors, transfusion medicine specialists, procurement leaders, and diagnostics vendors to surface practical constraints, adoption drivers, and implementation experiences. These qualitative inputs were supplemented by a structured review of public regulatory guidance, clinical validation reports, and device labeling to verify performance claims and pathway requirements.

Technology assessments evaluated analytical principles, operational characteristics, and interoperability features across platform types. Supply chain analysis examined manufacturing footprints, distribution channels, and tariff-sensitive procurement dependencies to understand risk vectors. Throughout the process, evidence was contextualized to reflect regional regulatory environments and typical end-user operational models. Findings were synthesized to emphasize actionable implications rather than abstract projections, and to support strategic decision-making for clinical, operational, and commercial stakeholders.

A clear and practical conclusion emphasizing evidence-driven adoption, supply chain resilience, and digital integration as the pillars of sustainable blood screening programs

Blood screening stands at the intersection of clinical necessity and technological possibility, requiring stakeholders to make disciplined choices that reconcile analytical performance with operational constraints. Emerging tools and enhanced connectivity offer opportunities to shorten detection windows, simplify workflows, and improve traceability, but successful adoption depends on tailored implementation strategies that reflect local infrastructure, staff competencies, and supply chain realities. Decision makers should therefore prioritize solutions that deliver both clinical value and operational viability.

In essence, the imperative is to adopt a pragmatic, evidence-driven approach: validate platforms within the context of intended use, strengthen supply chain governance to withstand policy shifts, and integrate digital workflows that support quality and interoperability. By doing so, healthcare organizations and diagnostic providers can ensure that blood screening systems are not only technologically advanced but also resilient, scalable, and closely aligned to patient safety objectives.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of AI-driven predictive analytics in blood disease screening workflows to improve detection accuracy
• 5.2. Expansion of at-home blood screening kits leveraging smartphone connectivity and remote lab integration for personalized health monitoring
• 5.3. Adoption of multiplex immunoassays for simultaneous detection of multiple blood markers enhancing diagnostic efficiency and throughput
• 5.4. Rising demand for point-of-care blood screening devices in rural and underserved regions to facilitate early disease detection
• 5.5. Development of next-generation sequencing panels for comprehensive blood-borne pathogen screening in transfusion services
• 5.6. Regulatory shifts driving harmonization of blood screening standards across emerging markets to streamline global testing protocols

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Screening Market, by Test Type

• 8.1. Hepatitis B Screening
• 8.2. Hepatitis C Screening
• 8.3. HIV Screening
• 8.4. Syphilis Screening

9. Blood Screening Market, by Technology

• 9.1. Chemiluminescence
• 9.2. Flow Cytometry
• 9.3. Immunoassays
  • 9.3.1. Chemiluminescence Immunoassay
  • 9.3.2. Enzyme Linked Immunosorbent Assay
  • 9.3.3. Radioimmunoassay
• 9.4. Molecular Diagnostics
  • 9.4.1. Isothermal Amplification
  • 9.4.2. Next Generation Sequencing
  • 9.4.3. Polymerase Chain Reaction

10. Blood Screening Market, by End User

• 10.1. Blood Banks
• 10.2. Clinics
• 10.3. Diagnostic Laboratories
• 10.4. Hospitals

11. Blood Screening Market, by Sample Type

• 11.1. Plasma
• 11.2. Serum
• 11.3. Whole Blood

12. Blood Screening Market, by Testing Mode

• 12.1. Lab Based
• 12.2. Point Of Care

13. Blood Screening Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Blood Screening Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Blood Screening Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. F. Hoffmann-La Roche Ltd
  • 16.3.2. Abbott Laboratories
  • 16.3.3. Siemens Healthineers AG
  • 16.3.4. Danaher Corporation
  • 16.3.5. Thermo Fisher Scientific Inc.
  • 16.3.6. Grifols, S.A.
  • 16.3.7. Bio-Rad Laboratories, Inc.
  • 16.3.8. Ortho Clinical Diagnostics, Inc.
  • 16.3.9. Hologic, Inc.
  • 16.3.10. Terumo BCT, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BLOOD SCREENING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. BLOOD SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BLOOD SCREENING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BLOOD SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BLOOD SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 167. AMERICAS BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 168. AMERICAS BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 169. AMERICAS BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 170. AMERICAS BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 171. AMERICAS BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 172. AMERICAS BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 173. AMERICAS BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 174. AMERICAS BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 185. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 186. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 187. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 188. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 189. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 190. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 204. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 205. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 206. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 244. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 255. AFRICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 256. AFRICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 259. AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 260. AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 261. AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 262. AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 271. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 274. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 275. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 277. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 287. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 288. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 289. ASEAN BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 290. ASEAN BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 291. ASEAN BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 292. ASEAN BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 293. ASEAN BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 294. ASEAN BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 299. ASEAN BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 300. ASEAN BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 304. ASEAN BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 305. GCC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 306. GCC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 307. GCC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 308. GCC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 309. GCC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 310. GCC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 311. GCC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 312. GCC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 313. GCC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 314. GCC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 315. GCC BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 316. GCC BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 317. GCC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 318. GCC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 319. GCC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 320. GCC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 321. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 322. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 323. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 324. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 325. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 326. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 327. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 328. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 329. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 330. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 331. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 332. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 333. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 334. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 335. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 336. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 337. BRICS BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 338. BRICS BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 339. BRICS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 340. BRICS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 341. BRICS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 342. BRICS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 343. BRICS BLOOD SCREENING MAR